S-OA-N
Oral Abstracts - Session N - Allogeneic Transplants
BMT Tandem "Scientific" Meeting
Texas B (Gaylord Texan)
Chairs:
Marcie Riches, MD, MS
and
Amin M. Alousi, MD
Disclosures:
M. Riches,
Algeta USA, Spouse is Senior Medical Director: Salary
A. M. Alousi,
Nothing To Disclose
Donor Telomere Length Predicts Recipient Survival after Allogeneic Hematopoietic Cell Transplantation in Patients with Bone Marrow Failure Syndromes
Shahinaz Gadalla, MD, PhD, National Cancer Institute;
Tao Wang, PhD, Medical College of Wisconsin;
Michael Haagenson, MS, CIBMTR;
Stephen R Spellman, MBS, Center for International Blood and Marrow Transplant Research;
Stephanie J. Lee, MD, MPH, Fred Hutchinson Cancer Research Center;
Kirsten M. Williams, MD, National Cancer Institute, NIH;
Jason Y Wong, Harvard School of Public Health;
Immaculata De Vivo, PhD, MPH, Harvard School of Public Health;
Sharon A Savage, MD, National Cancer Institute
Related PBSC Donors Age >60 Have High Rates of Baseline and Donation-Related Pain and Slow Recovery: First Report from the Related Donor Safety Study (RDSafe)
Michael A. Pulsipher, MD, Primary Children's Medical Center, University of Utah School of Medicine;
Pintip Chitphakdithai, PhD, National Marrow Donor Program;
Brent R. Logan, PhD, Medical College of Wisconsin;
Galen E. Switzer, PhD, University of Pittsburgh;
Marcie Riches, MD, MS, H. Lee Moffitt Cancer Center;
J. Douglas Rizzo, MD, MS, CIBMTR/Medical College of Wisconsin;
Paolo Anderlini, MD, The University of Texas MD Anderson Cancer Center;
Susan F. Leitman, MD, National Heart Lung and Blood Institute - NIH;
James W. Varni, PhD, Texas A&M University;
Amy Hays, MPH, RN, National Marrow Donor Program;
Hati Kobusingye, CIBMTR;
John P. Miller, MD, PhD, National Marrow Donor Program;
Rebecca J. Drexler, National Marrow Donor Program;
Roberta King, MPH, CIBMTR/Minneapolis Campus;
Mary M. Horowitz, MD, MS, CIBMTR and Medical College of Wisconsin;
Dennis L. Confer, MD, CIBMTR/National Marrow Donor Program;
Willis H. Navarro, MD, National Marrow Donor Program
Who Is the Best Haematopoietic Stem Cell Donor for a Male Patient with Acute Leukaemia?
Olle Ringden, MD, PhD, Karolinska Institutet;
Myriam Labopin, MD, Service d’Hématologie et Thérapie Cellulaire, AP-HP, UPMC Université Paris 6, UMR-S 938, CEREST-TC EBMT, Hôpital Saint Antoine;
Martin Solders, MD, Karolinska Institutet;
Dietrich W. Beelen, MD, University Hospital of Essen;
Renate Arnold, MD, Charité - Universitätsmedizin Berlin;
Gerhard Ehninger, Universitaetskinikum Dresden;
Noel Milpied, CHU Bordeaux;
Dietger Niederwieser, MD, University of Leipzig;
Rose-Marie Hamladji, MD, PhD, Center Pierre et Marie Curie;
Arnold Ganser, MD, Medizinische Hochschule Hannover;
Gerard Socié, MD, PhD, Hospital Saint Louis;
Matthias Stelljes, University of Münster;
Liisa Volin, MD, Helsinki University Central Hospital;
Charles Craddock, Queen Elizabeth Hospital;
Mohamad Mohty, CHU de Nantes - Hotel-Dieu
Sargramostim (GM-CSF) Combined with IV Plerixafor to Mobilize Peripheral Blood Stem Cells (PBSC) from Normal HLA-Matched Allogeneic Sibling Donors
Mark A. Schroeder, MD, Washington University School of Medicine;
Sarah Merida, Washington University School of Medicine;
David Schwab, Washington University School of Medicine;
Michael P. Rettig, PhD, Washington University School of Medicine;
Stephanie Meier, Washington University School of Medicine;
Sandra Lopez, MD, Washington University School of Medicine;
Kathryn Trinkaus, Ph.D., Washington University School of Medicine;
Geoffrey L. Uy, MD, Washington University School of Medicine;
Amanda Cashen, MD, Washington University School of Medicine;
Keith Stockerl-Goldstein, Washington University School of Medicine;
Peter Westervelt, MD, PhD, Washington University School of Medicine;
John F. DiPersio, MD, PhD, Washington University School of Medicine
Idiopathic Pneumonia Syndrome after HCT: Evidence of Occult Infectious Etiologies
Sachiko Seo, Fred Hutchinson Cancer Research Center;
Christian Renaud, Universite de Montreal;
Jane M Kuypers, University of Washington;
Meei-Li Huang, University of Washington;
Hu Xie, Fred Hutchinson Cancer Research Center;
Cynthia E Fisher, MD, MPH, Fred Hutchinson Cancer Research Center;
Robert C Hackman, MD, Fred Hutchinson Cancer Research Center;
David Myerson, MD, PhD, University of Washington Medical Center;
Yae-Jean Kim, Sungkyungkwan university;
Takahiro Fukuda, MD, National Cancer Center Hospital;
David N Fredricks, Fred Hutchinson Cancer Research Center;
David K. Madtes, MD, Fred Hutchinson Cancer Research Center;
Keith R Jerome, MD, PhD, University of Washington;
Michael J. Boeckh, MD, PhD, Fred Hutchinson Cancer Research Center
Infections Are the Major Cause of Non Relapse Mortality (NRM) after T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome
Roni Tamari, Memorial Sloan-Kettering Cancer Center;
Sean Devlin, PhD, Memorial Sloan-Kettering Cancer Center;
Jenna D. Goldberg, MD, Memorial Sloan-Kettering Cancer Center;
Patrick Hilden, PhD, Memorial Sloan-Kettering Cancer Center;
Ann A. Jakubowski, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Esperanza Papadopoulos, MD, Memorial Sloan-Kettering Cancer Center;
Doris M. Ponce, MD, Memorial Sloan-Kettering Cancer Center;
Craig Sauter, MD, Memorial Sloan-Kettering Cancer Center;
Jim Young, MD, Memorial Sloan-Kettering Cancer Center;
Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Hugo Castro-Malaspina, M.D., Memorial Sloan-Kettering Cancer Center
